Brief: Halozyme Withdraws Proposal To Acquire Evotec Following Evotec's Unwillingness To Engage In Discussions

Halozyme Therapeutics

22/11/2024 14:06

Nov 22 (Reuters) - Evotec SE  EVTG.DE :
    * HALOZYME WITHDRAWS PROPOSAL TO ACQUIRE EVOTEC FOLLOWING
EVOTEC'S
UNWILLINGNESS TO ENGAGE IN DISCUSSIONS
    * HALOZYME THERAPEUTICS INC: REITERATE RAISED 2024 GUIDANCE
FOR
REVENUE OF $970-$1,020 MILLION AND ADJUSTED EBITDA OF $595-$625
MILLION
    * HALOZYME THERAPEUTICS INC - TO DATE, EVOTEC HAS BEEN
UNWILLING
TO ENGAGE WITH US TO EXPLORE A POTENTIAL COMBINATION AND A
COMPANY SPOKESPERSON HAS PUBLICLY COMMENTED THAT ITS GOAL IS TO
REMAIN AN INDEPENDENT COMPANY

Source text:  ID:nPn4cwbXMa 
Further company coverage:  EVTG.DE 

 ((Reuters.Briefs@thomsonreuters.com;))